Skip to main content
Homepage
PARTIAL Analysis Report
Sep 4, 2026
58 days ago · 2% complete
Partial analysis — no complete end-to-end run on record.
No report run on this ticker yet Only preliminary foundational data below
NOT YET RESEARCHED No report has been run on GRAL yet. What you are seeing is foundational data only — price, profile and filings — not the full analysis (lenses, memo, scores and the AI panel arrive with the first report).
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for GRAIL, Inc. (GRAL) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysis — the core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at voiceoftrades.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

GRAIL, Inc.

GRAL NASDAQ
Healthcare · Diagnostics & Research
Menlo Park, CA 94025, United States grail.com Updated Nov 1, 8:16pm
Price
$80.62
Market Cap
$3.6B
Employees
910
Beta
3.25
Avg Volume
686,074
CEO
Dr. Joshua J. Ofman M.D., M.S.H.S

GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection testing and services. Its core offering is Galleri, a blood-based screening test designed to detect multiple cancer types before symptoms appear, supporting earlier clinical evaluation and diagnosis. The company uses next-generation sequencing, machine learning, software, and automation to analyze biological signals associated with cancer and deliver screening insights through laboratory and service workflows. GRAIL serves healthcare providers and patients in the United States and international markets, with its work centered on cancer screening, diagnostic support, and related laboratory services. Headquartered in Menlo Park, California, GRAIL plays a notable role in the expanding field of liquid biopsy and genomic diagnostics, where it contributes to efforts aimed at improving early cancer detection and broadening access to advanced screening technologies.

Runs with full report
Price Overview
Current data · timestamped when a report runs
$75.88
Change
+0.35 (+0.46%)
Day Range
$74.28 – $77.61
52-Week Range
$36.98 – $118.84
50-Day MA
$73.54
200-Day MA
$72.66
Volume
53,682.00
0Company Classification 1Industry Landscape 2Company Momentum 3Forward Projection 4aDCF Valuation 4bEarnings Power Value 4cAnchored PE 4dReverse DCF 4eRevenue-Based DCF 4fAnchored P/S 4gScenario Analysis 4hDividend Discount Model 4iBook Value Analysis 4jInsider Activity 4fCash Flow Quality 4gDebt Maturity Risk 4hMacro Environment 4iSector Intelligence 4jRevenue Confidence 4kSensitivity Analysis 4lSector Demand Cycle 5AI Investigation 5bThesis Evaluation 6Valuation Synthesis
computed not applicable not yet run 1 computed · 6 not applicable · 17 not yet run
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for GRAL — it's generated by the pipeline (market-narrative step).
Claude Reading
Claude Opus reviews the pipeline's raw data + every prior verdict, then writes an independent take.
No AI findings yet for GRAL — they're generated by the pipeline (ai-findings step) when a report is run on this ticker.
GPT Reading
GPT reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No GPT reading yet for GRAL — it's generated by the pipeline (gpt-critique step) after the other Big-3 seats, when a report is run on this ticker.
Grok Reading
Grok (xAI) reads the identical raw briefing blind — one of the Big-3 independent readings — and commits to its own verdict.
No Grok reading yet for GRAL — it's generated by the pipeline (grok-critique step) alongside the other Big-3 seats, when a report is run on this ticker.
Advanced Analysis Forensic deep-dive · separate lenses
A separate, manually-run forensic pipeline (dilution, earnings quality, liquidity → two scored lenses → the play). Hasn't been run for this ticker yet.
Community AI Feedback
No community reviews yet for GRAL. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this